

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:30:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 14:30:51 ON 09 NOV 2003

FILE 'EMBASE' ENTERED AT 14:30:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:30:51 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFR(3A) (III)

L1	24	FILE CAPLUS
L2	21	FILE BIOSIS
L3	26	FILE MEDLINE
L4	26	FILE EMBASE
L5	21	FILE USPATFULL

TOTAL FOR ALL FILES

L6	118	EGFR(3A) (III)
----	-----	----------------

=> l6(P)cancer

L7	7	FILE CAPLUS
L8	4	FILE BIOSIS
L9	8	FILE MEDLINE
L10	8	FILE EMBASE
L11	6	FILE USPATFULL

TOTAL FOR ALL FILES

L12	33	L6(P) CANCER
-----	----	--------------

=> l12 and (urine or serum or plasma or csf)

L13	1	FILE CAPLUS
L14	0	FILE BIOSIS
L15	0	FILE MEDLINE
L16	0	FILE EMBASE
L17	6	FILE USPATFULL

TOTAL FOR ALL FILES

L18	7	L12 AND (URINE OR SERUM OR PLASMA OR CSF)
-----	---	---

=> dup rem

ENTER L# LIST OR (END):l18

PROCESSING COMPLETED FOR L18

L19	7	DUP REM L18 (0 DUPLICATES REMOVED)
-----	---	------------------------------------

=> d l19 ibib abs total

L19 ANSWER 1 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:294379 USPATFULL

TITLE: Novel proteins and nucleic acids encoding same

INVENTOR(S): Alsobrook, John P., II, Madison, CT, UNITED STATES

Boldog, Ferenc L., North Haven, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

Casman, Stacie J., North Haven, CT, UNITED STATES

Grosse, William M., Branford, CT, UNITED STATES

Gusev, Vladimir Y., Madison, CT, UNITED STATES

Ji, Weizhen, Branford, CT, UNITED STATES

Lepley, Denise M., Branford, CT, UNITED STATES

Liu, Xiaohong, Branford, CT, UNITED STATES

Mezick, Amanda J., Hamden, CT, UNITED STATES

Padigaru, Muralidhara, Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Shen, Lei, Hamden, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Szekeres, Edward S., JR., Wallingford, CT, UNITED STATES
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207394	A1	20031106
APPLICATION INFO.:	US 2002-190115	A1	20020703 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-898994, filed on 3 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303168P	20010705 (60)
	US 2002-368996P	20020401 (60)
	US 2002-386816P	20020607 (60)
	US 2000-215854P	20000703 (60)
	US 2000-215856P	20000703 (60)
	US 2000-215902P	20000703 (60)
	US 2000-216585P	20000707 (60)
	US 2000-216586P	20000707 (60)
	US 2000-216722P	20000707 (60)
	US 2000-218622P	20000717 (60)
	US 2000-218992P	20000717 (60)
	US 2000-221285P	20000727 (60)
	US 2001-268734P	20010214 (60)
	US 2001-274260P	20010308 (60)
	US 2001-279856P	20010329 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Ivor R. Elrifi, Esq., Mintz, Levin, Cohn, Ferris,,
 Glovsky and Popeo, P.C., One Financial Center, Boston,
 MA, 02111

NUMBER OF CLAIMS: 52
 EXEMPLARY CLAIM: 1
 LINE COUNT: 10972

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L19 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:158932 USPATFULL

TITLE: Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist

INVENTOR(S): Rockwell, Patricia, West Redding, CT, UNITED STATES
 Goldstein, Neil I., Maplewood, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108545	A1	20030612
APPLICATION INFO.:	US 2002-91300	A1	20020304 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-798689, filed on 2 Mar 2001, PENDING Continuation-in-part of Ser. No. US 1999-401163, filed on 22 Sep 1999, GRANTED, Pat. No. US 6365157 Continuation of Ser. No. US 1997-967113, filed on 10 Nov 1997, GRANTED, Pat. No. US 6448077 Continuation of Ser. No. US 1997-779450, filed on 7 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-706804, filed on 3 Sep 1996, GRANTED, Pat. No. US 5861499 Continuation-in-part of Ser. No. US 1995-476533, filed on 7 Jun 1995, ABANDONED Continuation of Ser. No. US 1994-326552, filed on 20 Oct 1994, GRANTED, Pat. No. US 5840301 Continuation-in-part of Ser. No. US 1994-196041, filed on 10 Feb 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004		
NUMBER OF CLAIMS:	67		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Page(s)		
LINE COUNT:	4558		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	2001:748048 CAPLUS
DOCUMENT NUMBER:	135:283947
TITLE:	Cancer therapy patient classification based on microarray analysis of gene amplification or deletion using comparative genomic hybridization
INVENTOR(S):	Seelig, Steven A.
PATENT ASSIGNEE(S):	Vysis, Inc., USA
SOURCE:	PCT Int. Appl., 61 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075160	A1	20011011	WO 2001-US10063	20010329
W: AU, CA, CN, JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1268860	A1	20030102	EP 2001-964688	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRIORITY APPLN. INFO.:		US 2000-539400	A	20000331
		WO 2001-US10063	W	20010329
AB The method of the invention comprises the classification of a cancer patient population into various cancer therapy groups based on anal. by genomic DNA microarray of multiple gene amplifications or deletions present or absent in the diseased tissue of each patient. In particular, the invention involves patient				

classification into one of at least four **cancer** therapy groups based on the microarray anal. of gene amplification or gene deletion at multiple chromosome locations. The invention has the significant clin. advantage of guiding selection of expensive **cancer** adjuvant drugs for use with patients most likely to respond pos. to the individual drug. For example, a genomic DNA microarray simultaneously measuring 59 sep. gene amplifications or gene deletions in diseased tissue can be used to stratify solid tumor **cancer** patients, such as breast **cancer** patients, into at least nine groups: those most likely to respond to (i) anti-HER-2/neu therapy (Herceptin), (ii) anti-**EGFR** therapy (C225 antibody), (iii) anti-AKT1 therapy (cis-platin), (iv) anti-PIK3CA therapy, (v) anti-thymidylate synthase therapy (5-fluorouracil), (iv) anti-Topoisomerase II therapy (doxorubicin), (vii) anti-cmyc therapy, (viii) combination of anti-HER-2 therapy and anti-AKT1 therapy, and (ix) combination of anti-EGFR and anti-AKT1 therapy. The invention has the significant clin. advantage of guiding selection of expensive **cancer** adjuvant drugs for use with patients most likely to respond pos. to the individual drug or respond synergistically to a particular combination of adjuvant therapies. The invention has yet another advantage, compared to use of nucleic acid microarrays measuring only gene expression changes in the diseased tissue from normal tissue, of measuring changes in a more stable analyte-chromosomal DNA, than the labile mRNA necessary for gene expression anal.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2001:212420 USPATFULL

TITLE: Immunostimulatory nucleic acids for inducing a Th2 immune response

INVENTOR(S): McCluskie, Michael J., Ottawa, Canada
Davis, Heather L., Ottawa, Canada

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001044416	A1	20011122
APPLICATION INFO.:	US 2001-768012	A1	20010122 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177461P	20000120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Helen Lockhart, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210-2211	
NUMBER OF CLAIMS:	153	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	3831	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2001:63246 USPATFULL

TITLE: Reagent and processes for targeting mutant epidermal growth factor receptors

INVENTOR(S) : Wong, Albert J., Philadelphia, PA, United States
Moscatello, David K., Philadelphia, PA, United States
PATENT ASSIGNEE(S) : Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6224868	B1	20010501
APPLICATION INFO.:	US 1997-861423		19970521 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-347520, filed on 28 Nov 1994, now abandoned Continuation-in-part of Ser. No. WO 1995-US15401, filed on 28 Nov 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Seidel Gonda, Lavorgna & Monaco, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1237		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vaccines comprising peptides from a fusion junction present in a mutant human EGF receptor and methods of using these vaccines in the inhibition of tumor formation and enhancement of tumor regression are provided. Cell lines which overexpress a Type III mutant EGF receptor and methods of producing these cell lines are also provided. In addition, antibodies raised against peptides expressed by these cell lines are provided. Further, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of a mutant EGF receptor are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2001:22031 USPATFULL
TITLE: Oligonucleotide inhibition of epidermal growth factor receptor expression
INVENTOR(S) : Bennett, C. Frank, Carlsbad, CA, United States
Lipton, Allan, Hershey, PA, United States
Witters, Lois M., York Haven, PA, United States
PATENT ASSIGNEE(S) : Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
The Penn State Research Foundation, University Park, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6187585	B1	20010213
APPLICATION INFO.:	US 1999-306876		19990507 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-832658, filed on 4 Apr 1997, now patented, Pat. No. US 5914269		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
ASSISTANT EXAMINER:	McGarry, Sean		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	978		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression

of EGFR are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 1999:69658 USPATFULL
TITLE: Oligonucleotide inhibition of epidermal growth factor
receptor expression
INVENTOR(S): Bennett, C. Frank, Carlsbad, CA, United States
Lipton, Allan, Hershey, PA, United States
Witters, Lois M., York Haven, PA, United States
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, United States
(U.S. corporation)
The Penn State Research Foundation, University Park,
PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914269		19990622
APPLICATION INFO.:	US 1997-832658		19970404 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	McGarry, Sean		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris, LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	983		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.78	30.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

FILE 'AGRICOLA' ENTERED AT 14:34:55 ON 09 NOV 2003

FILE 'BIOTECHNO' ENTERED AT 14:34:55 ON 09 NOV 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 14:34:55 ON 09 NOV 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 14:34:55 ON 09 NOV 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:34:55 ON 09 NOV 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 14:34:55 ON 09 NOV 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

=> EGFRVIII and cancer and (serum, plasma, csf, or urine)

L20	0	FILE AGRICOLA
L21	0	FILE BIOTECHNO
L22	0	FILE CONFSCI
L23	0	FILE HEALSAFE
L24	0	FILE IMSDRUGCONF
L25	0	FILE LIFESCI
L26	0	FILE MEDICONF
L27	0	FILE PASCAL

TOTAL FOR ALL FILES

L28	0	EGFRVIII AND CANCER AND (SERUM, PLASMA, CSF, OR URINE)
-----	---	--

=> EGFRVIII

L29	0	FILE AGRICOLA
L30	63	FILE BIOTECHNO
L31	0	FILE CONFSCI
L32	0	FILE HEALSAFE
L33	0	FILE IMSDRUGCONF
L34	37	FILE LIFESCI
L35	0	FILE MEDICONF
L36	44	FILE PASCAL

TOTAL FOR ALL FILES

L37	144	EGFRVIII
-----	-----	----------

=> l37 and cancer

L38	0	FILE AGRICOLA
L39	40	FILE BIOTECHNO
L40	0	FILE CONFSCI
L41	0	FILE HEALSAFE
L42	0	FILE IMSDRUGCONF
L43	16	FILE LIFESCI
L44	0	FILE MEDICONF
L45	16	FILE PASCAL

TOTAL FOR ALL FILES

L46	72	L37 AND CANCER
-----	----	----------------

=> l46 and ELISA

L47	0	FILE AGRICOLA
L48	3	FILE BIOTECHNO
L49	0	FILE CONFSCI
L50	0	FILE HEALSAFE
L51	0	FILE IMSDRUGCONF
L52	1	FILE LIFESCI
L53	0	FILE MEDICONF

L54 2 FILE PASCAL

TOTAL FOR ALL FILES

L55 6 L46 AND ELISA

=> dup rem

ENTER L# LIST OR (END):l55

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L55

L56 5 DUP REM L55 (1 DUPLICATE REMOVED)

=> d l56 ibib abs total

L56 ANSWER 1 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2003:37102750 BIOTECHNO

TITLE: Generation of anti-idiotypic antibodies for application in clinical immunotherapy laboratory analyses

AUTHOR: Liu Z.; Panousis C.; Smyth F.E.; Murphy R.; Wirth V.; Cartwright G.; Johns T.G.; Scott A.M.

CORPORATE SOURCE: Dr. Z. Liu, Tumour Targeting Laboratory, Ludwig Institute for Cancer Research, Austin/Repatiation Medical Centre, 145-163 Studley Road, Heidelberg, Vic. 3084, Australia.

E-mail: zhanqi.liu@ludwig.edu.au

SOURCE: Hybridoma and Hybridomics, (2003), 22/4 (219-228), 31 reference(s)

CODEN: HHYYBF ISSN: 1536-8599

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 2003:37102750 BIOTECHNO

AB The chimeric monoclonal antibody ch806 specifically targets the tumor-associated mutant epidermal growth factor receptor (de 2-7EGFR or **EGFRVIII**) and is currently under investigation for its potential use in **cancer** therapy. The humanised monoclonal antibody hu3S193 specifically targets the Lewis Y epithelial antigen and is currently in Phase I clinical trials in patients with advanced breast, colon, and ovarian carcinomas. To assist the clinical evaluation of ch806 and hu3S193, laboratory assays are required to monitor their serum pharmacokinetics and quantitate any immune responses to the antibodies. Mice immunized with ch806 or hu3S193 were used to generate hybridomas producing antibodies with specific binding to ch806 or hu3S193 and competitive for antigen binding. These anti-idiotypic antibodies (designated Ludwig Melbourne Hybridomas, LMH) were investigated as reagents suitable for use as positive controls for HAHA or HACA analyses and for measuring hu3S193 or ch806 in human serum. Anti-idiotypes with the ability to concurrently bind two target antibody molecules were identified, which enabled the development of highly reproducible, sensitive, specific **ELISA** assays for determining serum concentrations of hu3S193 and ch806 with a 3 ng/mL limit of quantitation using LMH-3 and LMH-12, respectively. BIAcore analyses determined high apparent binding affinity for both idiotypes: LMH-3 binding immobilized hu3S193, $K_a = 4.76 \times 10^{sup.8} M^{sup.-sup.1}$; LMH-12 binding immobilised ch806, $K_a = 1.74 \times 10^{sup.9} M^{sup.-sup.1}$. Establishment of HAHA or HACA analysis of sera samples using BIAcore was possible using LMH-3 and LMH-12 as positive controls for quantitation of immune responses to hu3S193 or ch806 in patient sera. These anti-idiotypes could also be used to study the penetrance and binding of ch806 or hu3S193 to tumor cells through immunohistochemical analysis of tumor biopsies. The generation of anti-idiotypic antibodies capable of concurrently binding a target antibody on each variable domain provides reagents with high sensitivity for the assessment of safety and pharmacokinetic profiles of target

antibodies administered clinically.

L56 ANSWER 2, OF 5 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2002-0194513 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Generation of anti-idiotypic reagents in the **EGFRvIII** tumor-associated antigen system
AUTHOR: WIKSTRAND Carol J.; COLE Vanessa R.; CROTTY Laura E.; SAMPSON John H.; BIGNER Darell D.
CORPORATE SOURCE: Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, United States; Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
SOURCE: Cancer immunology and immunotherapy, (2002), 50(12), 639-652, 39 refs.
ISSN: 0340-7004 CODEN: CIIMDN
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: Germany, Federal Republic of
LANGUAGE: English
AVAILABILITY: INIST-16198, 354000102316040010

AN 2002-0194513 PASCAL

CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.

AB The use of anti-idiotypic (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2.beta.) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2.beta., as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2.beta. to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57Bl/ 6-B16mse**EGFRvIII** tumor model was investigated. Following vaccination with one Ab2.beta. mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2.beta. mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2.beta. mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII**-expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2.beta. mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII**-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 3 OF 5 LIFESCI COPYRIGHT 2003 CSA on STN

ACCESSION NUMBER: 2003:30690 LIFESCI

TITLE: Generation of anti-idiotypic reagents in the

EGFRvIII tumor-associated antigen system
AUTHOR: Wikstrand, C.J.; Cole, V.R.; Crotty, L.E.; Sampson, J.H.; Bigner, D.D.
CORPORATE SOURCE: Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, USA; E-mail: wikst001@mc.duke.edu
SOURCE: Cancer Immunology, Immunotherapy [Cancer Immunol., Immunother.], (20020200) vol. 50, no. 12, pp. 636-652. ISSN: 0340-7004.
DOCUMENT TYPE: Journal
FILE SEGMENT: F
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The use of anti-idiotypic (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2 beta) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2 beta , as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2 beta to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57Bl/6-B16mse**EGFRvIII** tumor model was investigated. Following vaccination with one Ab2 beta mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2 beta mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2 beta mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII**-expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2 beta mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII**-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 4 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2001:34146569 BIOTECHNO
TITLE: Generation of anti-idiotypic reagents in the **EGFRvIII** tumor-associated antigen system
AUTHOR: Wikstrand C.J.; Cole V.R.; Crotty L.E.; Sampson J.H.; Bigner D.D.
CORPORATE SOURCE: C.J. Wikstrand, Department of Pathology, Box 3156, Duke University Medical Center, Durham, NC 27710, United States. E-mail: wikst001@mc.duke.edu
SOURCE: Cancer Immunology, Immunotherapy, (2001), 50/12 (639-652), 39 reference(s)
CODEN: CIIMDN ISSN: 0340-7004
DOCUMENT TYPE: Journal; Article
COUNTRY: Germany, Federal Republic of
LANGUAGE: English

SUMMARY LANGUAGE: English

AN 2001:34146569 BIOTECHNO

AB The use of anti-idiotypic (anti-id) vaccines for immunotherapy of human **cancers** is attractive, as immunization with true anti-id reagents (Ab2.beta.) has been shown to induce both cellular and humoral immunity, frequently when the original antigen does not, or when a state of anergy to the self-expressed tumor-associated antigen exists. The aim of this study was to investigate the potential of an anti-id vaccine approach to the glioma-associated antigen epidermal growth factor receptor variant III (**EGFRvIII**) for human clinical trials. By using conventional methodology, seven rat mAbs specific for the binding site of the murine anti-**EGFRvIII**-specific mAb Y10, as defined by the ability to inhibit the binding of mAb Y10 to **EGFRvIII** expressed on cells or as purified protein, were generated, and a subset (3/7) was found to be true Ab2.beta., as defined by the ability to induce the formation of antibody directed against **EGFRvIII** in two species (mouse and rabbit) when used as immunogen. The ability of these three Ab2.beta. to elicit a protective anti-tumor response when used as a vaccine in the syngeneic, subcutaneous C57Bl/6-B16mse**EGFRvIII** tumor model was investigated. Following vaccination with one Ab2.beta. mAb (2C7), 6/20 mice failed to develop tumor upon challenge, and 3/20 mice with outgrowing tumors exhibited dramatic regression of incipient tumors. Vaccination with a second mAb (5G8) resulted in one tumor-free survivor and one tumor regressor; vaccination with the third Ab2.beta. mAb (7D3) did not confer protection, but did significantly increase the latency period until tumor outgrowth in all vaccinated recipients. The ability of Ab2.beta. mAb 2C7 to induce an anti-**EGFRvIII** response in non-human primates was investigated by using the saponin adjuvant approved for human clinical trial, QS-21. Three of three macaques produced anti-**EGFRvIII** titers, as detected on **EGFRvIII**-expressing cells by both **ELISA** and fluorescence-activated cytometric analysis, following six immunizations with Ab2.beta. mAb 2C7 and QS-21. The results obtained confirm that an anti-id response in the **EGFRvIII** antigen system can be induced in rodents, rabbits, and non-human primates, and it may prove a useful adjunct to immunotherapeutic approaches to **EGFRvIII**-positive gliomas, breast carcinomas, and non-small-cell lung tumors.

L56 ANSWER 5 OF 5 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1995:25216942 BIOTECHNO

TITLE: Monoclonal antibodies against **EGFRvIII** are tumor specific and react with breast and lung carcinomas and malignant gliomas

AUTHOR: Wikstrand C.J.; Hale L.P.; Batra S.K.; Hill M.L.; Humphrey P.A.; Kurpad S.N.; McLendon R.E.; Moscatello D.; Pegram C.N.; Reist C.J.; Traweek S.T.; Wong A.J.; Zalutsky M.R.; Bigner D.D.

CORPORATE SOURCE: Pathology Department, Duke University Medical Center, Box 3156, Durham, NC 27710, United States.

SOURCE: Cancer Research, (1995), 55/14 (3140-3148)

CODEN: CNREA8 ISSN: 0008-5472

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1995:25216942 BIOTECHNO

AB Despite molecular biological advances in understanding human **cancers**, translation into therapy has been less forthcoming; targeting neoplastic cells still requires that tumor-specific markers, preferably those on the cell surface, be identified. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, **EGFRvIII**, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas. Specific polyvalent

antisera to the extracellular portion of the variant were readily induced, but immunization using a synthetic linear peptide representing the unique **EGFRvIII** primary sequence has been unsuccessful in mice or macaques. We report here five specific monoclonal antibodies (mAbs) developed through long-term immunization protocols using the **EGFRvIII**-specific synthetic peptide and the intact variant in different formats that maintained secondary and tertiary conformation. These mAbs identify the **EGFRvIII** on the cell surface with relatively high affinity (K(A) range, 0.13 to 2.5×10^{10} M⁻¹) by live cell Scatchard analysis. These mAbs are specific for **EGFRvIII** as determined by RIA, ELISA, Western blot, analytical flow cytometry, autophosphorylation, and immunohistochemistry. Isolating specific mAbs enabled us to analyze normal and neoplastic human tissue and establish that **EGFRvIII** is truly tumor specific for subsets of breast carcinomas and for previously reported non-small cell lung carcinomas and gliomas. Also, this receptor is not expressed by any normal human tissues thus far examined, including elements of the peripheral, central nervous, and lymphoid systems. With mAbs, we identified a higher incidence of **EGFRvIII** positivity in gliomas than previously described and identified an **EGFRvIII**-positive subset of breast tumors; also, we observed that the **EGFRvIII** epitope is not expressed in normal tissues, and we demonstrated the localizing and therapeutic potential of the mAbs for tumors expressing this epitope. Our observations strongly warrant development of this mAb-antigen system as therapy for breast, lung, and central nervous system tumors.

=> file .chemistry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
14.08	45.07

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.65

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 14:39:01 ON 09 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 14:39:01 ON 09 NOV 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 14:39:01 ON 09 NOV 2003
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 14:39:01 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFRVIII AND CANCER
L57 37 FILE CAPLUS

L58 40 FILE BIOTECHNO
L59 0 FILE COMPENDEX
L60 0 FILE ANABSTR
L61 0 FILE CERAB
L62 0 FILE METADEX
L63 52 FILE USPATFULL

TOTAL FOR ALL FILES

L64 129 EGFRVIII AND CANCER

=> l64 and ELISA

L65 4 FILE CAPLUS
L66 3 FILE BIOTECHNO
L67 0 FILE COMPENDEX
L68 0 FILE ANABSTR
L69 0 FILE CERAB
L70 0 FILE METADEX
L71 41 FILE USPATFULL

TOTAL FOR ALL FILES

L72 48 L64 AND ELISA

=> l72 and (serum or plasma or csf or urine)

L73 2 FILE CAPLUS
L74 1 FILE BIOTECHNO
L75 0 FILE COMPENDEX
L76 0 FILE ANABSTR
L77 0 FILE CERAB
L78 0 FILE METADEX
L79 41 FILE USPATFULL

TOTAL FOR ALL FILES

L80 44 L72 AND (SERUM OR PLASMA OR CSF OR URINE)

=> dup rem

ENTER L# LIST OR (END):l80

PROCESSING COMPLETED FOR L80

L81 43 DUP REM L80 (1 DUPLICATE REMOVED)

=> l81 and py<2002

L82 2 S L81
L83 1 FILE CAPLUS
L84 0 S L81
L85 0 FILE BIOTECHNO
L86 0 S L81
L87 0 FILE COMPENDEX
L88 0 S L81
L89 0 FILE ANABSTR
L90 0 S L81
L91 0 FILE CERAB
L92 0 S L81
L93 0 FILE METADEX
L94 41 S L81
L95 13 FILE USPATFULL

TOTAL FOR ALL FILES

L96 14 L81 AND PY<2002

=> dup rem

ENTER L# LIST OR (END):l96

PROCESSING COMPLETED FOR L96

L97 14 DUP REM L96 (0 DUPLICATES REMOVED)

=> d l97 ibib abs total

L97 ANSWER 1 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:297455 USPATFULL
TITLE: Methods and compositions for making dendritic cells
from expanded populations of monocytes and for
activating T cells
INVENTOR(S): Nelson, Edward L., Eldersburg, MD, United States
Strobl, Susan L, Hagerstown, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the
Secretary of the Department of Health and Human
Services, Washington, DC, United States (U.S.
government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6479286	B1	20021112	
	WO 9853048		19991126	<--
APPLICATION INFO.:	US 2000-424173		20000605	(9)
	WO 1999-US9810311		19990520	
			20000605	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47348P	19970521 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ketter, James	
ASSISTANT EXAMINER:	Li, Q Janice	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	2385	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of generating IL-3 expanded populations of monocytes and
differentiating the cells into dendritic cells are provided. The methods
include use of the dendritic cells to activate T-cells, in vitro and in
vivo, and for ex vivo and other therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:693382 CAPLUS
DOCUMENT NUMBER: 135:256132
TITLE: Sensitive detection of wild-type and mutant EGFR by
specific ELISA assays in any biological
sample
INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David
K.; Lipton, Allan
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312 <--

EP 1276771 A1 20030122 EP 2001-918548 20010312

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY, TR

PRIORITY APPLN. INFO.:

US 2000-188424P P 20000310

WO 2001-US7766 W 20010312

AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L97 ANSWER 3 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:218198 USPATFULL

TITLE: Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample

INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Leitzel, Kim E., Hummelstown, PA, United States
Moscatello, David K., Philadelphia, PA, United States
Lipton, Allan, Hershey, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001046686	A1	20011129	<--
APPLICATION INFO.:	US 2001-803854	A1	20010312	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-188424P	20000310 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS JEFFERSON UNIVERSITY, INTELLECTUAL PROPERTY DIVISION, 1020 WALNUT STREET, SUITE 620, PHILADELPHIA, PA, 19107	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	475	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention generally relates a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biological samples, a method of detecting **cancers** and other diseases in biological samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 4 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:152725 USPATFULL

TITLE: Fusion proteins for protein delivery

INVENTOR(S): Davis, Pamela B., Cleveland Heights, OH, United States
Ferkol, Thomas, Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
Schreiber, John, Gates Mills, OH, United States
Luk, John M., South Horizons, Hong Kong
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6287817	B1	20010911	<--
APPLICATION INFO.:	US 2000-559393		20000426	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041
Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900
Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Park, Hankyel T.
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 5 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:121518 USPATFULL
TITLE: Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
INVENTOR(S): Schneck, Jonathan, Silver Spring, MD, United States
Pardoll, Drew, Brookeville, MD, United States
O'Herrin, Sean, Baltimore, MD, United States
Slansky, Jill, Baltimore, MD, United States
Greten, Tim, Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6268411	B1	20010731	<--
APPLICATION INFO.:	US 1998-150622		19980910	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Bansal, Geetha P.			
LEGAL REPRESENTATIVE:	Banner & wittcoff, Ltd.			
NUMBER OF CLAIMS:	104			
EXEMPLARY CLAIM:	1,69			
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 24 Drawing Page(s)			
LINE COUNT:	1814			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the .sup.pep MHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.

.sup.pep MHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These .sup.pep MHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and

have uses as specific regulators of immune responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 6 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:112055 USPATFULL
TITLE: Bifunctional molecules for delivery of therapeutics
INVENTOR(S): Davis, Pamela B., Cleveland heights, OH, United States
Ferkol, Jr., Thomas W., Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6261787	B1	20010717	<--
APPLICATION INFO.:	US 1999-264032		19990308	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041 Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900 Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Park, Hankyel T.			
LEGAL REPRESENTATIVE:	Banner & Witcoff LTD			
NUMBER OF CLAIMS:	16			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)			
LINE COUNT:	1650			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:75367 USPATFULL
TITLE: Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
INVENTOR(S): Paul, Sudhir, 7900 Cambridge, 14-1G, Houston, TX, United States 77054
Gololobov, Gennady, 5500 N. Braeswood, Apt. 259, Houston, TX, United States 77096
Smith, Larry J., 7824 Jackson St., Omaha, NE, United States 68114

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6235714	B1	20010522	<--
APPLICATION INFO.:	US 1998-46373		19980323	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Huff, Sheela			
LEGAL REPRESENTATIVE:	Dann, Dorfman, Herrell and Skillman			
NUMBER OF CLAIMS:	13			

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 3997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 8 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2001:63246 USPATFULL
TITLE: Reagent and processes for targeting mutant epidermal growth factor receptors
INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Moscatello, David K., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6224868	B1	20010501	<--
APPLICATION INFO.:	US 1997-861423		19970521	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-347520, filed on 28 Nov 1994, now abandoned Continuation-in-part of Ser. No. WO 1995-US15401, filed on 28 Nov 1995			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Ulm, John			
LEGAL REPRESENTATIVE:	Seidel Gonda, Lavorgna & Monaco, P.C.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	1237			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vaccines comprising peptides from a fusion junction present in a mutant human EGF receptor and methods of using these vaccines in the inhibition of tumor formation and enhancement of tumor regression are provided. Cell lines which overexpress a Type III mutant EGF receptor and methods of producing these cell lines are also provided. In addition, antibodies raised against peptides expressed by these cell lines are provided. Further, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of a mutant EGF receptor are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 9 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2000:134582 USPATFULL
TITLE: Epidermal growth factor receptor antibodies
INVENTOR(S): Wels, Winfried S., Emmendingen, Germany, Federal Republic of
Schmidt, Mathias, Freiburg, Germany, Federal Republic of
Vakalopoulou, Evangelia, Berlin, Germany, Federal Republic of
Schneider, Douglas W., Lafayette, CA, United States
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6129915 20001010 <--
 APPLICATION INFO.: US 1999-296595 19990423 (9)
 RELATED APPLN. INFO.: Division of Ser. No. US 1997-800198, filed on 13 Feb 1997, now patented, Pat. No. US 5942602
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Huff, Sheela
 ASSISTANT EXAMINER: Helms, Larry R.
 LEGAL REPRESENTATIVE: Millen, White, Zelano, & Branigan, P.C.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 25 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 1091

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as **cancer** and cellular hyper proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 10 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 2000:131598 USPATFULL
 TITLE: Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors
 INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
 Bigner, Darell, Mebane, NC, United States
 PATENT ASSIGNEE(S): The Johns Hopkins University, United States (U.S. corporation)
 Duke University, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6127126		20001003	<--
APPLICATION INFO.:	US 1999-264723		19990309	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 which is a continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990 which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Srivastava, Devah			
LEGAL REPRESENTATIVE:	Banner & Wifcoff, Ltd.			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 30 Drawing Page(s)			
LINE COUNT:	2152			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 11 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 2000:70969 USPATFULL
 TITLE: Fusion proteins for protein delivery
 INVENTOR(S): Davis, Pamela B., Cleveland Heights, OH, United States

Ferkol, Thomas, Concord, OH, United States
 Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
 Schreiber, John, Gates Mills, OH, United States
 Luk, John M., South Horizons, Hong Kong
 PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6072041		20000606 <--
APPLICATION INFO.:	US 1997-957333		19971024 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996 And Ser. No. US 1996-656906, filed on 3 Jun 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Park, Hankyel		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	1210		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 12 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 1999:142132 USPATFULL
 TITLE: Structural alterations of the EGF receptor gene in human tumors
 INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
 Bigner, Darell, Mebane, NC, United States
 PATENT ASSIGNEE(S): The Johns Hopkins Univiersity, Baltimore, MD, United States (U.S. corporation)
 Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981725		19991109 <--
APPLICATION INFO.:	US 1995-479808		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992 which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Kaufman, Claire M.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	11		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	2161		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER: 1999:99750 USPATFULL
TITLE: Growth factor receptor antibodies
INVENTOR(S): Wels, Winfried S., Emmendingen, Germany, Federal Republic of
Schmidt, Mathias, Freiburg, Germany, Federal Republic of
Vakalopoulou, Evangelia, Berlin, Germany, Federal Republic of
Schneider, Douglas W, Lafayette, CA, United States
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5942602		19990824	<--
APPLICATION INFO.:	US 1997-800198		19970213	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Scheiner, Toni R.			
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.			
NUMBER OF CLAIMS:	25			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 13 Drawing Page(s)			
LINE COUNT:	1184			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as **cancer** and cellular hyper proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L97 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER: 1999:43184 USPATFULL
TITLE: Membrane-bound cytokine compositions comprising GM-CSF and methods of modulating an immune response using same
INVENTOR(S): Hoo, William Soo, Carlsbad, CA, United States
PATENT ASSIGNEE(S): The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5891432		19990406	<--
APPLICATION INFO.:	US 1997-902516		19970729	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Spector, Lorraine			
LEGAL REPRESENTATIVE:	Campbell & Flores LLP			
NUMBER OF CLAIMS:	24			
EXEMPLARY CLAIM:	1,13			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)			
LINE COUNT:	1917			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody

immunomodulatory molecule such as GM-CSF operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L Number	Hits	Search Text	DB	Time stamp
1	37	EGFRvIII same cancer	USPAT; US-PGPUB; EPO; DERWENT	2003/11/09 14:50
2	36	(EGFRvIII same cancer) and (urine or plasma or serum or csf)	USPAT; US-PGPUB; EPO; DERWENT	2003/11/09 14:50

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal641cxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:52:46 ON 09 NOV 2003

=> file .jacob

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 15:52:55 ON 09 NOV 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:52:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 15:52:55 ON 09 NOV 2003

FILE 'EMBASE' ENTERED AT 15:52:55 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:52:55 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> EGFRVIII(P)cancer
L1          34 FILE CAPLUS
L2          30 FILE BIOSIS
L3          31 FILE MEDLINE
L4          31 FILE EMBASE
L5          33 FILE USPATFULL
```

TOTAL FOR ALL FILES
L6 159 EGFRVIII(P) CANCER

```
=> dup rem
ENTER L# LIST OR (END):l1-l4
PROCESSING COMPLETED FOR L1
PROCESSING COMPLETED FOR L2
PROCESSING COMPLETED FOR L3
PROCESSING COMPLETED FOR L4
L7          51 DUP REM L1-L4 (75 DUPLICATES REMOVED)
```

```
=> l7 and (plasma or urine or csf or extract or sputum)
L8          34 S L7
L9          1 FILE CAPLUS
L10         12 S L7
L11         0 FILE BIOSIS
L12         3 S L7
L13         0 FILE MEDLINE
L14         2 S L7
L15         0 FILE EMBASE
L16         0 S L7
L17         0 FILE USPATFULL
```

TOTAL FOR ALL FILES
L18 1 L7 AND (PLASMA OR URINE OR CSF OR EXTRACT OR SPUTUM)

=> d l18 ibib abs total

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:693382 CAPLUS
DOCUMENT NUMBER: 135:256132
TITLE: Sensitive detection of wild-type and mutant EGFR by
specific ELISA assays in any biological sample
INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David
K.; Lipton, Allan
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312
EP 1276771	A1	20030122	EP 2001-918548	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRIORITY APPLN. INFO.:			US 2000-188424P	P 20000310
			WO 2001-US7766	W 20010312

AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE): ignore

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
18.54	18.75

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-0.65	-0.65

CA SUBSCRIBER PRICE

FILE 'AGRICOLA' ENTERED AT 15:55:19 ON 09 NOV 2003

FILE 'BIOTECHNO' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:55:19 ON 09 NOV 2003

COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 15:55:19 ON 09 NOV 2003

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

```
=> EGFRVIII(P)  CANCER
L19             0  FILE AGRICOLA
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)  CANCER'
L20             40 FILE BIOTECHNO
L21             0  FILE CONFSCI
L22             0  FILE HEALSAFE
L23             0  FILE IMSDRUGCONF
L24             16 FILE LIFESCI
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)  CANCER'
L25             0  FILE MEDICONF
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)  CANCER'
L26             16 FILE PASCAL
```

```
TOTAL FOR ALL FILES
L27             72 EGFRVIII(P)  CANCER
```

```
=> l27 and (plasma or urine or csf or extract or sputum)
L28             0  FILE AGRICOLA
L29             0  FILE BIOTECHNO
L30             0  FILE CONFSCI
L31             0  FILE HEALSAFE
L32             0  FILE IMSDRUGCONF
L33             0  FILE LIFESCI
L34             0  FILE MEDICONF
L35             0  FILE PASCAL
```

```
TOTAL FOR ALL FILES
L36             0  L27 AND (PLASMA OR URINE OR CSF OR EXTRACT OR SPUTUM)
```

```
=> l27 and (urine, plasma, csf, sputum, extract)
L37             0  FILE AGRICOLA
L38             0  FILE BIOTECHNO
L39             0  FILE CONFSCI
L40             0  FILE HEALSAFE
L41             0  FILE IMSDRUGCONF
L42             0  FILE LIFESCI
L43             0  FILE MEDICONF
L44             0  FILE PASCAL
```

```
TOTAL FOR ALL FILES
L45             0  L27 AND (URINE, PLASMA, CSF, SPUTUM, EXTRACT)
```

```
=> file .chemistry\
'.CHEMISTRY\' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'AGRICOLA, BIOTECHNO, CONFSCI, HEALSAFE, IMSDRUGCONF,
LIFESCI, MEDICONF, PASCAL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

```
=> file .chemistry
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                6.43      25.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                               ENTRY      SESSION
CA SUBSCRIBER PRICE                0.00      -0.65
```

```
FILE 'CAPLUS' ENTERED AT 15:56:51 ON 09 NOV 2003
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 15:56:51 ON 09 NOV 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 15:56:51 ON 09 NOV 2003
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 15:56:51 ON 09 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> EGFRVIII(P)(cancer or carcinoma or tumor)
L46 79 FILE CAPLUS
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L47 57 FILE BIOTECHNO
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L48 0 FILE COMPENDEX
L49 0 FILE ANABSTR
L50 0 FILE CERAB
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRVIII(P)(CANCER'
L51 0 FILE METADEX
L52 49 FILE USPATFULL

TOTAL FOR ALL FILES
L53 185 EGFRVIII(P)(CANCER OR CARCINOMA OR TUMOR)

=> l53 and (plasma or urine or csf or sputum)
L54 1 FILE CAPLUS
L55 0 FILE BIOTECHNO
L56 0 FILE COMPENDEX
L57 0 FILE ANABSTR
L58 0 FILE CERAB
L59 0 FILE METADEX
L60 35 FILE USPATFULL

TOTAL FOR ALL FILES
L61 36 L53 AND (PLASMA OR URINE OR CSF OR SPUTUM)

=> dup rem
ENTER L# LIST OR (END):l61
PROCESSING COMPLETED FOR L61
L62 36 DUP REM L61 (0 DUPLICATES REMOVED)

=> d l54 ibib abs total

L54 ANSWER 1 OF 1 CAPLUS. COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:693382 CAPLUS
DOCUMENT NUMBER: 135:256132

TITLE: Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample
 INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David K.; Lipton, Allan
 PATENT ASSIGNEE(S): Thomas Jefferson University, USA
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312
EP 1276771	A1	20030122	EP 2001-918548	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2000-188424P P 20000310
 WO 2001-US7766 W 20010312

AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> l60 and (urine or plasma)
 L63 1 FILE CAPLUS
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRvIII(P) (CANCER'
 L64 0 FILE BIOTECHNO
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRvIII(P) (CANCER'
 L65 0 FILE COMPENDEX
 L66 0 FILE ANABSTR
 L67 0 FILE CERAB
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EGFRvIII(P) (CANCER'
 L68 0 FILE METADEX
 L69 27 FILE USPATFULL

TOTAL FOR ALL FILES
 L70 28 L60 AND (URINE OR PLASMA)

=> l70 and py<2003
 L71 1 FILE CAPLUS
 L72 0 FILE BIOTECHNO
 L73 0 FILE COMPENDEX
 L74 0 FILE ANABSTR
 L75 0 FILE CERAB
 L76 0 FILE METADEX
 L77 20 FILE USPATFULL

TOTAL FOR ALL FILES
 L78 21 L70 AND PY<2003

=> l78 and ELISA

L79 1 FILE CAPLUS
 L80 0 FILE BIOTECHNO
 L81 0 FILE COMPENDEX
 L82 0 FILE ANABSTR
 L83 0 FILE CERAB
 L84 0 FILE METADEX
 L85 14 FILE USPATFULL

TOTAL FOR ALL FILES

L86 15 L78 AND ELISA

=> d l86 ibib abs total

L86 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:693382 CAPLUS

DOCUMENT NUMBER: 135:256132

TITLE: Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample

INVENTOR(S): Wong, Albert J.; Leitzel, Kim E.; Moscatello, David K.; Lipton, Allan

PATENT ASSIGNEE(S): Thomas Jefferson University, USA

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068711	A1	20010920	WO 2001-US7766	20010312 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2001046686	A1	20011129	US 2001-803854	20010312 <--
EP 1276771	A1	20030122	EP 2001-918548	20010312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 2000-188424P P 20000310

WO 2001-US7766 W 20010312

AB The present invention generally relates to a method of detecting type III mutant EGF receptor (**EGFRvIII**) in biol. samples, a method of detecting **cancers** and other diseases in biol. samples, and to a method of assessing treatment and selecting therapy for **cancer** patients.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:297455 USPATFULL

TITLE: Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells

INVENTOR(S): Nelson, Edward L., Eldersburg, MD, United States
 Strobl, Susan L, Hagerstown, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479286	B1	20021112 <--

	WO 9853048	19991126	<--
APPLICATION INFO.:	US 2000-424173	20000605	(9)
	WO 1999-US9810311	19990520	
		20000605	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47348P	19970521 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ketter, James	
ASSISTANT EXAMINER:	Li, Q Janice	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	2385	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of generating IL-3 expanded populations of monocytes and differentiating the cells into dendritic cells are provided. The methods include use of the dendritic cells to activate T-cells, in vitro and in vivo, and for ex vivo and other therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:254045 USPATFULL
 TITLE: Molecular complexes which modify immune responses
 INVENTOR(S): Schneck, Jonathan, Silver Spring, MD, United States
 O'Herrin, Sean, Madison, WI, United States
 Lebowitz, Michael S., Pikesville, MD, United States
 Hamad, Abdel, Ellicott City, MD, United States
 PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458354	B1	20021001 <--
APPLICATION INFO.:	US 2000-668143		20000925 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-324782, filed on 3 Jun 1999 Continuation-in-part of Ser. No. US 1998-63276, filed on 21 Apr 1998, now patented, Pat. No. US 6140113 Continuation-in-part of Ser. No. US 1997-828712, filed on 28 Mar 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14367P	19960328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bansal, Geetha P.	
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	2579	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating

disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 4 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:246722 USPATFULL
TITLE: Structural alterations of the EGF receptor genes in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6455498	B1	20020924	<--
APPLICATION INFO.:	US 2000-664752		20000919	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-264723, filed on 9 Mar 1999, now patented, Pat. No. US 6127126 Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned Continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Spector, Lorraine			
ASSISTANT EXAMINER:	Andres, Janet L.			
LEGAL REPRESENTATIVE:	Banner & Witcoff Ltd.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	39 Drawing Figure(s); 30 Drawing Page(s)			
LINE COUNT:	2135			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:227904 USPATFULL
TITLE: In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
INVENTOR(S): Zauderer, Maurice, Pittsford, NY, UNITED STATES
Smith, Ernest S., Ontario, NY, UNITED STATES
PATENT ASSIGNEE(S): University of Rochester, Rochester, NY, 14642 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002123057	A1	20020905	<--
APPLICATION INFO.:	US 2001-987456	A1	20011114	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249268P	20001117 (60)
	US 2001-262067P	20010118 (60)
	US 2001-271424P	20010227 (60)
	US 2001-298087P	20010615 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK
AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 83
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 7215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:191201 USPATFULL
TITLE: Uses of monoclonal antibody 8H9
INVENTOR(S): Cheung, Nai-Kong V., Purchase, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002102264	A1	20020801	<--
APPLICATION INFO.:	US 2001-982645	A1	20011018	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-241344P	20001018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Albert Wai-Kit Chan, 141-07 20th Ave. Suite 604, Whitestone, NY, 11357	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Page(s)	
LINE COUNT:	6128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 7 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:148255 USPATFULL

TITLE: Membrane-bound cytokine compositions and methods of
modulating an immune response using same
INVENTOR(S): Hoo, William Soo, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002076392	A1	20020620	<--
	US 6482407	B2	20021119	
APPLICATION INFO.:	US 2001-847185	A1	20010501	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-201931, filed on 1 Dec 1998, PENDING Continuation of Ser. No. US 1997-902516, filed on 29 Jul 1997, GRANTED, Pat. No. US 5891432			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122			
NUMBER OF CLAIMS:	46			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	4 Drawing Page(s)			
LINE COUNT:	1978			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:112301 USPATFULL
TITLE: Human anti-epidermal growth factor receptor
single-chain antibodies
INVENTOR(S): Raisch, Kevin Paul, Birmingham, AL, UNITED STATES
Curiel, David T., Birmingham, AL, UNITED STATES
Bonner, James Alan, Vestavia Hills, AL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002058033	A1	20020516	<--
APPLICATION INFO.:	US 2001-976118	A1	20011012	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240353P	20001013 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1063	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by **ELISA** as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and/or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and/or diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:22438 USPATFULL
TITLE: Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
INVENTOR(S): Paul, Sudhir, Houston, TX, UNITED STATES
Gololobov, Gennady, Houston, TX, UNITED STATES
Smith, Larry J., Omaha, NE, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002013274	A1	20020131	<--
APPLICATION INFO.:	US 2001-862849	A1	20010522	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-46373, filed on 23 Mar 1998, GRANTED, Pat. No. US 6235714			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	DANN DORFMAN HERRELL & SKILLMAN, SUITE 720, 1601 MARKET STREET, PHILADELPHIA, PA, 19103-2307			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	15 Drawing Page(s)			
LINE COUNT:	3950			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:218198 USPATFULL
TITLE: Sensitive detection of wild-type and mutant EGFR by specific **ELISA** assays in any biological sample
INVENTOR(S): Wong, Albert J., Philadelphia, PA, United States
Leitzel, Kim E., Hummelstown, PA, United States
Moscatello, David K., Philadelphia, PA, United States
Lipton, Allan, Hershey, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001046686	A1	20011129	<--
APPLICATION INFO.:	US 2001-803854	A1	20010312	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-188424P	20000310 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: THOMAS JEFFERSON UNIVERSITY, INTELLECTUAL PROPERTY
DIVISION, 1020 WALNUT STREET, SUITE 620, PHILADELPHIA,
PA, 19107

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 475

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention generally relates a method of detecting type III
mutant EGF receptor (**EGFRvIII**) in biological samples, a method
of detecting **cancers** and other diseases in biological samples,
and to a method of assessing treatment and selecting therapy for
cancer patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:112055 USPATFULL
TITLE: Bifunctional molecules for delivery of therapeutics
INVENTOR(S): Davis, Pamela B., Cleveland heights, OH, United States
Ferkol, Jr., Thomas W., Concord, OH, United States
Eckman, Elizabeth, Ponte Vedra Beach, FL, United States
PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United
States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6261787	B1	20010717	<--
APPLICATION INFO.:	US 1999-264032		19990308	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-957333, filed on 24 Oct 1997, now patented, Pat. No. US 6072041 Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996, now patented, Pat. No. US 5972900 Continuation-in-part of Ser. No. US 1996-656906, filed on 3 Jun 1996, now patented, Pat. No. US 5972901			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Park, Hankyel T.			
LEGAL REPRESENTATIVE:	Banner & Witcoff LTD			
NUMBER OF CLAIMS:	16			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)			
LINE COUNT:	1650			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A bifunctional molecule consisting of a therapeutic molecule and a
ligand which specifically binds a transcytotic receptor can be
transported specifically from the basolateral surface of epithelial
cells to the apical surface. This approach provides the ability to
deliver a therapeutic molecule directly to the apical surface of the
epithelium, by targeting the transcytotic receptor with an appropriate
ligand. Thus, the highest concentration of the therapeutic molecule will
be at the apical surface, where it can have the greatest therapeutic
effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:75367 USPATFULL
TITLE: Methods for identifying inducers and inhibitors of
proteolytic antibodies, compositions and their uses
INVENTOR(S): Paul, Sudhir, 7900 Cambridge, 14-1G, Houston, TX,
United States 77054
Gololobov, Gennady, 5500 N. Braeswood, Apt. 259,
Houston, TX, United States 77096

Smith, Larry J., 7824 Jackson St., Omaha, NE, United States 68114

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6235714	B1	20010522	<--
APPLICATION INFO.:	US 1998-46373		19980323	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Huff, Sheela			
LEGAL REPRESENTATIVE:	Dann, Dorfman, Herrell and Skillman			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 15 Drawing Page(s)			
LINE COUNT:	3997			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2000:131598 USPATFULL
TITLE: Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors
INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
Bigner, Darell, Mebane, NC, United States
PATENT ASSIGNEE(S): The Johns Hopkins University, United States (U.S. corporation)
Duke University, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6127126		20001003	<--
APPLICATION INFO.:	US 1999-264723		19990309	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-479808, filed on 7 Jun 1995, now patented, Pat. No. US 5981725 which is a continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992, now abandoned which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990 which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Srivastava, Devah			
LEGAL REPRESENTATIVE:	Banner & Wifcoff, Ltd.			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 30 Drawing Page(s)			
LINE COUNT:	2152			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 1999:142132 USPATFULL
 TITLE: Structural alterations of the EGF receptor gene in human tumors
 INVENTOR(S): Vogelstein, Bert, Baltimore, MD, United States
 Bigner, Darell, Mebane, NC, United States
 PATENT ASSIGNEE(S): The Johns Hopkins Univiersity, Baltimore, MD, United States (U.S. corporation)
 Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981725		19991109 <--
APPLICATION INFO.:	US 1995-479808		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-896909, filed on 11 Jun 1992 which is a continuation of Ser. No. US 1990-531410, filed on 1 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-404226, filed on 8 Sep 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Kaufman, Claire.M.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	11		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	2161		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Deletions in the EGF-R gene are found in many gliomas, breast tumors, and lung tumors. A particular truncated EGFR protein has been found in many tumors and provides diagnostic and therapeutic modalities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L86 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 1999:43184 USPATFULL
 TITLE: Membrane-bound cytokine compositions comprising GM-CSF and methods of modulating an immune response using same
 INVENTOR(S): Hoo, William Soo, Carlsbad, CA, United States
 PATENT ASSIGNEE(S): The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5891432		19990406 <--
APPLICATION INFO.:	US 1997-902516		19970729 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
LEGAL REPRESENTATIVE:	Campbell & Flores LLP		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1,13		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1917		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule such as GM-CSF operatively fused to a heterologous membrane attachment domain. Non-antibody immunomodulatory molecules useful in the invention include immunostimulatory and immunosuppressive molecules such as cytokines. In one embodiment, the invention provides a cellular vaccine having a membrane-bound fusion

protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain and, additionally, a disease-associated antigen or immunogenic epitope thereof. Further provided by the invention are methods of modulating an immune response against a disease-associated antigen by administering to an individual a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane attachment domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.